Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.
复制标题
DOI：
10.1002/gps.2723
复制
发表时间：
2012-04
影响因子：
4
通讯作者：
Lyketsos, Constantine G.
中科院分区：
文献类型：
--
作者：
Leoutsakos, Jeannie-Marie S.;Muthen, Bengt O.;Breitner, John C. S.;Lyketsos, Constantine G.
We examined effects of non-steroidal anti-inflammatory drugs (NSAID) on cognitive decline as a function of phase of pre-clinical Alzheimer’s disease (AD). Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer’s disease. We fit growth mixture models of Modified Mini-Mental State Examination (3MS) trajectories with data from 2,388 participants in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT), and included class-specific effects of naproxen and celecoxib. We identified 3 classes: “no-decline”, “slow-decline”, and “fast-decline”, and examined effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (−2 log likelihood difference: 369.23; p<0.001), but resulted in reversal of effects over time. Over four years, participants in the slow-decline class on placebo typically lost 6.6 3MS points, while those on naproxen lost 3.1 points (p-value for difference: 0.19). Participants in the fast-decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p-value for difference from placebo: 0.04), while those on naproxen showed a typical decline of 24.9 points (p-value for difference from placebo: <0.0001). Our results appeared statistically robust, but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then to attenuate change in fast decliners.
登录
查看更多内容
影响因子：
2.8
作者：
Fennema-Notestine C;McEvoy LK;Hagler DJ Jr;Jacobson MW;Dale AM;The Alzheimer's Disease Neuroimaging Initiative
通讯作者：
The Alzheimer's Disease Neuroimaging Initiative
影响因子：
9.9
作者：
Elkins, J. S.;Longstreth, W. T., Jr.;Johnston, S. C.
通讯作者：
Johnston, S. C.
影响因子：
3.7
作者：
de Jong, Danielle;Jansen, Rene;Kremer, Berry
通讯作者：
Kremer, Berry
DOI：
10.1111/j.1751-9004.2007.00054.x
发表时间：
2008-01-01
影响因子：
4.6
作者：
Jung, Tony;Wickrama, K. A. S.
通讯作者：
Wickrama, K. A. S.
影响因子：
--
作者：
Aizenstein, Howard Jay;Nebes, Robert D.;Saxton, Judith A.;Price, Julie C.;Mathis, Chester A.;Tsopelas, Nicholas D.;Ziolko, Scott K.;James, Jeffrey A.;Snitz, Beth E.;Houck, Patricia R.;Bi, Wenzhu;Cohen, Ann D.;Lopresti, Brian J.;DeKosky, Steven T.;Halligan, Edythe M.;Klunk, William E.
通讯作者：
Klunk, William E.